Evidence map›Paper›PMID 39056437›Full record

ArticleHealth technology assessment (Winchester, England)2024

Accuracy of glomerular filtration rate estimation using creatinine and cystatin C for identifying and monitoring moderate chronic kidney disease: the eGFR-C study.

Edmund J Lamb, Jonathan Barratt, Elizabeth A Brettell, Paul Cockwell, R Nei Dalton, Jon J Deeks, Gillian Eaglestone, Tracy Pellatt-Higgins, Philip A Kalra, Kamlesh Khunti and 12 more

Abstract read
In one paragraph

Article in Health technology assessment (Winchester, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Testosterone deficiency and chronic kidney disease.Journal of clinical & translational endocrinology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Edmund J LambClinical Biochemistry, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK.ORCID 0000-0002-5154-7351
Jonathan BarrattDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-9063-7229
Elizabeth A BrettellBirmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-0669-3085
Paul CockwellRenal Medicine, Queen Elizabeth Hospital Birmingham and Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.ORCID 0000-0003-1975-266X
R Nei DaltonWellChild Laboratory, Evelina London Children's Hospital, St. Thomas' Hospital, London, UK.ORCID 0000-0001-9201-5266
Jon J DeeksBirmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-8850-1971
Gillian EaglestoneKent Kidney Care Centre, East Kent Hospitals University NHS Foundation Trust, Kent, UK.ORCID 0000-0001-9860-8679
Tracy Pellatt-HigginsCentre for Health Services Studies, University of Kent, Canterbury, UK.ORCID 0000-0002-2543-461X
Philip A KalraDepartment of Renal Medicine, Salford Royal Hospital Northern Care Alliance NHS Foundation Trust, Salford, UK.ORCID 0000-0001-7652-1572
Kamlesh KhuntiDiabetes Research Centre, University of Leicester, Leicester, UK.ORCID 0000-0003-2343-7099
Fiona C LoudKidney Care UK, Alton, UK.ORCID 0000-0001-7706-5396
Ryan S OttridgeBirmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-8685-2145
Aisling PotterClinical Biochemistry, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK.ORCID 0000-0003-4366-1039
Ceri RoweClinical Biochemistry, East Kent Hospitals University NHS Foundation Trust, Canterbury, UK.ORCID 0000-0002-6150-1816
Katie ScandrettTest Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0001-6111-2805
Alice J SitchTest Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0001-7727-4497
Paul E StevensKent Kidney Care Centre, East Kent Hospitals University NHS Foundation Trust, Kent, UK.ORCID 0000-0001-7606-0649
Claire C SharpeFaculty of Life Sciences and Medicine, King's College London, London, UK.ORCID 0000-0003-1704-8492
Bethany ShinkinsAcademic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.ORCID 0000-0001-5350-1018
Alison SmithAcademic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.ORCID 0000-0001-7709-1869
Andrew J SuttonAcademic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK.ORCID 0000-0001-7008-4770
Maarten W TaalDepartment of Renal Medicine, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK.ORCID 0000-0002-9065-212X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Estimation of glomerular filtration rate using equations based on creatinine is widely used to manage chronic kidney disease. In the UK, the Chronic Kidney Disease Epidemiology Collaboration creatinine equation is recommended. Other published equations using cystatin C, an alternative marker of kidney function, have not gained widespread clinical acceptance. Given higher cost of cystatin C, its clinical utility should be validated before widespread introduction into the NHS. Objectives: Primary objectives were to: (1) compare accuracy of glomerular filtration rate equations at baseline and longitudinally in people with stage 3 chronic kidney disease, and test whether accuracy is affected by ethnicity, diabetes, albuminuria and other characteristics; (2) establish the reference change value for significant glomerular filtration rate changes; (3) model disease progression; and (4) explore comparative cost-effectiveness of kidney disease monitoring strategies. Design: A longitudinal, prospective study was designed to: (1) assess accuracy of glomerular filtration rate equations at baseline ( Setting: Primary, secondary and tertiary care. Participants: Adults (≥ 18 years) with stage 3 chronic kidney disease. Interventions: Estimated glomerular filtration rate using the Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease equations. Main outcome measures: Measured glomerular filtration rate was the reference against which estimating equations were compared with accuracy being expressed as P30 (percentage of values within 30% of reference) and progression (variously defined) studied as sensitivity/specificity. A regression model of disease progression was developed and differences for risk factors estimated. Biological variation components were measured and the reference change value calculated. Comparative costs of monitoring with different estimating equations modelled over 10 years were calculated. Results: Accuracy (P30) of all equations was ≥ 89.5%: the combined creatinine-cystatin equation (94.9%) was superior ( Limitations: Recruitment of people from South Asian and African-Caribbean backgrounds was below the study target. Future work: Prospective studies of the value of cystatin C as a risk marker in chronic kidney disease should be undertaken. Conclusions: Inclusion of cystatin C in glomerular filtration rate-estimating equations marginally improved accuracy but not detection of disease progression. Our data do not support cystatin C use for monitoring of glomerular filtration rate in stage 3 chronic kidney disease. Trial registration: This trial is registered as ISRCTN42955626. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 11/103/01) and is published in full in

Indexed as

CreatinineCystatin CDisease ProgressionGlomerular Filtration RateRenal Insufficiency, ChronicAdultAgedAlbuminuriaBiomarkersCost-Benefit AnalysisFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesBiomarkersCreatinineCystatin CADULTALBUMINURIACHRONIC KIDNEY DISEASECHRONIC RENAL INSUFFICIENCYCOST-BENEFIT ANALYSISCREATININECYSTATIN CDIABETES MELLITUSDISEASE PROGRESSIONETHNICITYGLOMERULAR FILTRATION RATEHUMANSKIDNEYPROSPECTIVE STUDIESRISK FACTORSUNITED KINGDOM

Identifiers

PMID39056437
PMCPMC11331378

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.